New Hope for Breast Cancer Patients: Indian Study Paves the Way for Targeted Therapies

A groundbreaking Indian study has identified three key genetic mutations—TP53, PIK3CA, and ESR1—linked to resistance in ER/PR+HER2- breast cancer, the most common subtype in India. Conducted at Tata Memorial Hospital, researchers used whole genome sequencing to analyze tumor samples from patients whose cancer relapsed despite hormone therapy. These findings could help predict treatment resistance early, enabling personalized care and reducing overtreatment. Additionally, the study highlights potential for repurposing DNA repair-targeting drugs to improve outcomes for resistant cases.

 

Source: Indian Express, nature.com